Highly Potent HIV-1 Protease Inhibitors

Back to all technologies
Download as PDF
2019-GHOS-68467
There is a need to develop new treatments for patients living with HIV-1, as HIV-1 rapidly acquires resistance to treatment options. Researchers at Purdue University have developed a new class of HIV-1 protease inhibitors. Compared to darunavir, a leading FDA approved drug, these compounds were 100 times more potent in cell culture. Additionally, the compounds have improved metabolic stability over previous protease inhibitors. The primary application for these compounds is for the treatment of multidrug-resistant HIV-1.

Advantages:
-Improved potency against HIV-1
-Improved pharmacokinetic properties

Potential Applications:
-HIV/AIDS treatment

Publication: Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities
ACS Med. Chem. Lett. 2020, 11, 1965−1972
https://doi.org/10.1021/acsmedchemlett.9b00670
Jul 15, 2021
NATL-Patent
United States
(None)
(None)

Jan 15, 2020
PCT-Gov. Funding
WO
(None)
(None)

Jan 15, 2019
Provisional-Patent
United States
(None)
(None)

(None)
NATL-Patent
Europe
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org